Nuformix announces collaboration with Magnus Life Science

7th December 2014

Nuformix is pleased to announce it has entered a collaboration with Magnus Life Science to develop novel co-crystals of a lead Magnus compound. Magnus Life Science is a life sciences company based on ground-breaking clinical and academic research, some of which originated from University College London (UCL). Nuformix will identify and characterise novel cocrystals to potentially enhance the physiochemical properties of Magnus’ compound(s), with potential to expand its use, and generate new intellectual property. Magnus Life Science Chief Executive Officer Dr David Campbell said: “Nuformix is a leader in cocrystallisation and we look forward to working with them as we seek to strengthen our IP and further differentiate our therapeutic portfolio.” Nuformix Chief Executive Officer Dr Dan Gooding said: “We are extremely pleased to be working with Magnus Life Science. They have a clear goal of bringing innovation to unmet needs based on world-class science. We believe our technology fits the goal well and can make a significant contribution.”